Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P52298
UPID:
NCBP2_HUMAN
Alternative names:
20 kDa nuclear cap-binding protein; Cell proliferation-inducing gene 55 protein; NCBP 20 kDa subunit; NCBP-interacting protein 1
Alternative UPACC:
P52298; B2RE91; B4DMK7; E9PAR5; Q14924; Q2TS50
Background:
Nuclear cap-binding protein subunit 2, also known as NCBP 20 kDa subunit, plays a pivotal role in RNA metabolism, including pre-mRNA splicing, translation regulation, and mRNA export. It forms part of the cap-binding complex (CBC), essential for mRNA export from the nucleus and a pioneer round of mRNA translation critical for nonsense-mediated mRNA decay (NMD). Additionally, it participates in microRNA biogenesis and acts as a negative regulator of mRNA deadenylation.
Therapeutic significance:
Understanding the role of Nuclear cap-binding protein subunit 2 could open doors to potential therapeutic strategies.